[Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005119
Original Title: Belantamab-Mafodotin (multiples Myelom) - Bewertung gemäß § 35a Abs. 1 Satz 11 SGB V (Ablauf Befristung)
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Multiple Myeloma
  • Antineoplastic Agents
  • Antibodies, Monoclonal, Humanized
  • Belantamab Mafodotin
  • Multiple Myeloma
  • Health Care Costs
  • Epidemiology
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: <p>Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.